tiprankstipranks
Trending News
More News >
Contineum Therapeutics, Inc. Class A (CTNM)
:CTNM
US Market
Advertisement

Contineum Therapeutics, Inc. Class A (CTNM) Income Statement

Compare
176 Followers

Contineum Therapeutics, Inc. Class A Income Statement

Last quarter (Q1 2025), Contineum Therapeutics, Inc. Class A's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q1, Contineum Therapeutics, Inc. Class A's net income was $-15.99M. See Contineum Therapeutics, Inc. Class A’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 50.00M$ 0.00$ 0.00
Gross Profit
$ 0.00$ 50.00M$ -329.00K$ 0.00
Operating Expenses
$ 50.89M$ 66.08M$ 22.39M$ 28.65M
Depreciation and Amortization
$ 258.00K$ 195.00K$ 329.00K$ 325.00K
EBITDA
$ -42.00M$ 23.57M$ -23.54M$ -28.34M
Operating Income
$ -50.89M$ -16.08M$ -22.72M$ -28.65M
Other Income/Expenses
$ 8.64M$ 39.25M$ -1.53M$ -354.00K
Pretax Income
$ -42.26M$ 23.17M$ -24.25M$ -29.00M
Net Income
$ -42.26M$ 22.72M$ -24.25M$ -29.00M
Per Share Metrics
Basic EPS
$ -2.18$ 0.90$ -0.97$ -1.15
Diluted EPS
$ -2.18$ 0.90$ -0.97$ -1.15
Weighted Average Shares Outstanding
19.35M 25.28M 25.13M 25.13M
Weighted Average Shares Outstanding (Diluted)
19.35M 25.28M 25.13M 25.13M
Currency in USD

Contineum Therapeutics, Inc. Class A Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis